Strategic expansion The company is expanding capabilities with new quantitative testing for 7-Hydroxymitragynine in oral fluid, indicating a move to broaden test panels and offer more comprehensive drug screening services to clients and partners.

Public sector alignment Past collaborations with state legislators and government bodies for COVID-19 antibody testing demonstrate a proven track record of working with public sector clients, suggesting potential opportunities for government contracts or state-funded health initiatives.

Healthcare partnerships Active collaboration with Meijer and availability of rapid, accurate oral fluid testing positions the company to expand with large retailers, employers, and healthcare networks seeking convenient drug testing solutions.

Technology leverage Utilization of a modern tech stack including cloud, analytics and web platforms points to scalable, secure testing operations and favorable integration with client systems, supporting large-scale deployments and enterprise sales conversations.

Strategic fit and scale With mid-size footprint and revenue in the multiple tens of millions, the company sits between SMB and large enterprise, presenting a compelling cross-sell and upsell path for companion services, compliance offerings, and enterprise-grade testing programs.